ADCC Mediated B-Cell dEpletion and BAFF-R Blockade (AMBER)
Autoimmune Hepatitis / Posted 6 months ago
Patients will be randomly assigned to different doses of VAY736 or placebo. The primary analysis is planned at 24 weeks. A subsequent study part will then test the efficacy and safety of VAY736 in a parallel group design. For this part of the trial a new group of autoimmune hepatitis patients will be enrolled.